Skip to main content

Exhibitor Press Releases

100OP25 Header

21 Feb 2025

AGEPHA Pharma launches MACUSAN A2: A dietary supplement developed with essential nutrients to reduce progression of Age-Related Macular Degeneration (AMD)

AGEPHA Pharma FZ-LLC Stand: E63
AGEPHA Pharma launches MACUSAN A2: A dietary supplement developed with essential nutrients to reduce progression of Age-Related Macular Degeneration (AMD)
AGEPHA Pharma is excited to announce the launch of MACUSAN A2

AGEPHA Pharma is excited to announce the launch of MACUSAN A2, a new dietary supplement designed to meet the unique nutritional needs of patients with Age-Related Macular Degeneration (AMD).

Key Features of MACUSAN A2:

  • Clinically proven formulation: Based on the renowned AREDS2 study, ensuring efficacy and safety.
  • Essential nutrients: Includes Lutein, Zeaxanthin, Zinc oxide, Copper oxide, Vitamin E, and Vitamin C, which are vital for maintaining eye health.
  • Convenient daily dosage: Two capsules per day
  • Competitive pricing: Offers an affordable solution for patients seeking to manage AMD.
  • Recommended by Eye Health Professionals: Trusted and recommended by experts in the field.

For more information, please visit www.macusan.com or contact maelis.robin@agephapharma.com

 

About Agepha Pharma

AGEPHA Pharma is a European pharmaceutical company specialised in multiple therapeutic areas, with a primary focus on ophthalmology.

Known for the reintroduction of aciclovir 3% eye ointment in the United Kingdom, AGEPHA Pharma offers a comprehensive range of ophthalmic products, including prescription medications and over-the-counter products.

 

Contact:

Maelis Robin     

Marketing Manager

maelis.robin@agephapharma.com

www.macusan.com

Contact Exhibitor about this Press Release

Loading

OFFICIAL UK PARTNER

OFFICIAL UK PARTNER

Official Associate Partner

Official Associate Partner

Official Associate Partner

MEDIA PARTNERS

 

 



 

Digital Media Partners


 

Accommodation Partner